AstraZeneca/Amgen's brodalumab branches out to psoriatic arthritis
This article was originally published in Scrip
Executive Summary
AstraZeneca and Amgen have upped the ante in the burgeoning anti-IL17 field with positive Phase II data for their investigational compound brodalumab in the additional indication of psoriatic arthritis published in the New England Journal of Medicine and due to be presented at the EULAR meeting in Paris on 14 June. However, larger studies of longer duration are necessary to assess adverse events associated with the product, the researchers said.